Literature DB >> 9758287

Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans.

J Vincent1, L Dogolo, B A Baris, S A Willavize, R Teng.   

Abstract

A simplified dosing algorithm for trovafloxacin was evaluated following a single-dose infusion of alatrofloxacin at trovafloxacin equivalent doses of 30, 100, 200, 300 and 400 mg (57 subjects), and multiple doses of 200, 300 and 400 mg (30 subjects). Maximum serum concentration and area under the concentration-time curve for trovafloxacin increased with dose. Trovafloxacin clearance (82-85 ml x h/kg) and volume of distribution (1.3-1.6 l/kg) were independent of dose. Infusion of alatrofloxacin at a trovafloxacin equivalent dose of 300 mg at 1, 2 or 3 mg/ml over 1 h did not alter the pharmacokinetics of trovafloxacin. A plot of the weight-adjusted dose of trovafloxacin in individual subjects against the maximum serum concentration following single and multiple dosing, indicated that the maximum serum concentration increased 1 microg/ml for each 1 mg/kg of trovafloxacin administered. Thus, a prior knowledge of the desired serum concentration will permit appropriate dosing without the use of complex nomograms in patients with normal hepatic function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9758287     DOI: 10.1007/bf01691577

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

1.  In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.

Authors:  D Felmingham; M J Robbins; K Ingley; I Mathias; H Bhogal; A Leakey; G L Ridgway; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

2.  In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae.

Authors:  K Klugman; A Wasas
Journal:  J Antimicrob Chemother       Date:  1995-11       Impact factor: 5.790

3.  Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.

Authors:  H P Endtz; J W Mouton; J G den Hollander; N van den Braak; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.

Authors:  T D Gootz; K E Brighty; M R Anderson; B J Schmieder; S L Haskell; J A Sutcliffe; M J Castaldi; P R McGuirk
Journal:  Diagn Microbiol Infect Dis       Date:  1994-08       Impact factor: 2.803

5.  In vitro activity of the new fluoroquinolone CP-99,219.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.

Authors:  B B Gooding; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

7.  Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.

Authors:  R Teng; S C Harris; D E Nix; J J Schentag; G Foulds; T E Liston
Journal:  J Antimicrob Chemother       Date:  1995-08       Impact factor: 5.790

8.  Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.

Authors:  A E Stuck; F J Frey; P Heizmann; R Brandt; E Weidekamm
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

9.  Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography.

Authors:  R Teng; T G Tensfeldt; T E Liston; G Foulds
Journal:  J Chromatogr B Biomed Appl       Date:  1996-01-12

10.  In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.

Authors:  A E Girard; D Girard; T D Gootz; J A Faiella; C R Cimochowski
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

View more
  2 in total

Review 1.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Safety of trovafloxacin in treatment of lower respiratory tract infections.

Authors:  D Williams; S Hopkins
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.